Lipodystrophy Syndrome: The Morphologic and Metabolic Effects of Antiretroviral Therapy in HIV Infection

Journal of the Association of Nurses in AIDS Care

Volumn 15, Issue 6, 2004, Pages 46-64

  Norris, Angela ^a   Dreher, H Michael ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

hyperlipidemia; insulin resistance; lipoatrophy; lipodystrophy syndrome

Indexed keywords

BODY COMPOSITION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; RISK FACTORS;

EID: 16644403195     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1177/1055329004271187     Document Type: Article

References (120)

1. Aboulafia D., and Bundow D. Buffalo hump in a patient with the acquired immunodeficiency syndrome. The New England Journal of Medicine 339 (1998) 1297
2. Aldeen T., Wells C., Hay P., Davidson F., and Lau R. Lipodystrophy associated with nevirapine-containing antiretroviral therapies. AIDS 13 (1999) 865
3. Amard, P. (2000, September) The effects of polylactic acid (PLA) as therapy for lipoatrophy of the face(Abstract No. P94). Abstract presented at the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada.
4. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (2003) s33-s50. http://care.diabetesjournals.org/cgi/content/full/26/suppl_1/s33 Retrieved April 17, 2003, from http://care.diabetesjournals.org/cgi/content/full/26/suppl_1/s33
5. Anderson J., Armstead R., Baker C., Barr D., Bozzette S. Carpenter. et al: (2002). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Retrieved February 28, 2002, from http://www.hivatis.org
6. Arevalo, J. (2002, April) Surgical therapy with polyacrylamide gel of facial atrophy. Abstract at Roundtable discussion on plastic surgery presented at the 3rd European Lipodystrophy Conference in Marbella, Spain.
7. Aubron-Olivier, C., Balantin, M. A., Laglenne E., Pauchard M., Katz P., Costagliola D., et al: (2001, October)Benefit of polylactic acid implant (Newfill) in severe facial lipoatrophy. Abstract presented at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece.
8. Barzilai N., She L., Liu B.Q., Vuguin P., Cohen P., Wang J., et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 48 (1999) 94-98
9. Behrens G., Dejam A., Schmidt H., Balks H., Brabant G., Korner T., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13 (1999) F63-F70
10. Behrens, G. M. N. Boerner, A. R., Wever, K, Brabant, G., et al: (2002, February)Impaired glucose phosphorylation in skeletal muscle causes insulin resistance in HIV-1 infected patients with lipodystrophy(Abstract No. LB11). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
11. Bickel, M., Rickerts, V, Klauke, S, Gould, J, Goldbach, J, Miller, V., (2000, September) The protra study: Switch fromPI to abacavir (ABC) and efavirenz (EFV) in HIV-1 infected adults previously treated with 2 NRTIs and a PI with undetectable HIV-RNA levels (vRNA)(Abstract No. 1531). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
12. Bollens, D., Guiguet, M, Tangre, P, Rachline, R. A., Meynard, J. L., Benlian, P., (2001, December)Family history, immuno-infectious status and type of antiretroviral drug regimen are predictors for major hypertriglyceridemia in HIV infected patients(Abstract No. I-220). Abstract presented at the 41st Interscience Conference on Antimicrobrial Agents and Chemotherapy, Chicago, IL.
13. Butt, A. A., Justice A. C., Fultz, S. L. (2003) Hepatitis C increases the risk of DM in HIV-infected veterans in care(Abstract No. 836). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
14. Calza, L., Manfredi, F. (2002, July) Use of fibrates and statins in the treatment of hyperlipidemia in HIV-infected patients receiving HAART(Abstract No. TuPeB4498). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
15. Carr, A. (2002, February) An objective case definition of HIV lipodystrophy(Abstract No. 31). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
16. Carr A., Hudson J., Chuah J., Mallal S., Law M., Hoy J., et al. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 15 (2001) 1811-1822
17. Carr, A., Puls, R, Law, M., the HIV Lipodystrophy Case Definition Study Group. (2003, February). An objective comparison of physician-and patient-rated severity of HIV lipodystrophy(Abstract No. 731). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
18. Carr A., Workman C., Smith D.E., Hoy J., Hudson J., Doong N., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. Journal of the American Medical Association 288 (2002) 207-215
19. Casado, J. L. Arrizabalaga, J, Antela, A, Iribarren, J. A., Moreno, A, Dronda, F., (2001, February) Long-term efficacy and tolerance of switching the protease inhibitor for nonnucleoside reverse transcriptase inhibitors: A 52-week, multicenter, prospective study(Abstract No. 673). Abstract presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
20. Cherry, C., Nolan, D, James, I, Mallal, S, McKinnon, E, French, M., (2003, February) Longitudinal associations between antiretroviral treatments and quantification of tissue mitochondrial DNA from ambulatory subjects with HIV infection(Abstract No. 133). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
21. Chowdhury, N., Ragha van S., Levine K., Iqbal S., Im A. El-Sadr, W. (2002, July)Prevalence of body fat distribution and metabolic alterations in cohort of African Americans and Latinos(Abstract No. B10310). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
22. Christeff, N., Truchis P., Melchior J. C., Gougeon, M. L. (2001, February) The clinical evolution of lipodystrophy syndrome is closely related to cortisol: DHEA ratio and serumIFN-α(Abstract No. 660). Abstract presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
23. Cohen, C., Shen Y., Rode R., Cameron D. W., Mellors J., Farthin C., et al: (2002, February) Effect of nucleoside (NRTI) intensification of prevalence of morphologic abnormalities (MoAs) at year 5 of ritonavir (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort(Abstract No. 683-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
24. Collins E., Wagner C., and Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader 10 (2000) 546-550
25. Currier J., Carpenter C., Daar E., Kotler D., and Wanke C. Identifying and managing morphologic complications of HIV and HAART [Continuing Medical Educational Brochure]. Learn More About It (2001), Serono Symposia International, Rockland, MA
26. Currier J. S. (2001). Metabolic complications of antiretroviral therapy and HIV infection. Medscape HIV/AIDS: Annual Update 2001. Retrieved January 17, 2002, from http://www.medscape.com/Medscape/HIV/AnnualUpdate/2001/mha07.curr/mha07.curr-o1.html
27. Currier, J. S., Boyd F., Kawabata H., Dezii C., Burtcel B., Hodder, S. (2002, February) Diabetes mellitus in HIV-infected individuals(Abstract No. 677-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
28. Day, J. N., Raabe A., Shiner A. M., Wilkins, E. G. (2002, July) Intradermal polylactic acid for severe HIV-associated facial lipoatrophy: Preliminary results(Abstract No. B10294). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
29. DeLorenze, G. N., Horberg M., Karter A. J., Ferrara A., Quesenberry C. P., Tsai, A. L. (2003, February) Incidence and prevalence of diabetes mellitus among HIV-infected patients in northern California's largest HMO(Abstract No. 44). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
30. Dennett, S., Richter Y., Jordan J., Carranza Rosenweig, J., Mahajan, S. (2000, September) US costs of managing abnormal fat distribution and metabolic abnormalities(Abstract No. 126). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
31. Dieterich D.T. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Reader 13 (2003) 176-184 187-187
32. Duran S., Saves M., Spire B., Cailleton V., Sobel A., Carrieri P., et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 15 (2001) 2441-2444
33. Engelhard, P., Knies, M. (2002, July) Safety and efficacy of New-Fill (polylactic acid) in the treatment of HIV-associated lipoatrophy(Abstract No. WePeB6011). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
34. Falusi O.M., and Aberg J.A. HIV and cardiovascular risk factor. AIDS 11 (2001) 263-268
35. Faultz, J. M., Hatzakis, G. E. (2000, September) Association of clinical profiles and insulin resistance patterns in HIV-infected patients with the HIV/HAART associated lipodystrophy syndrome (HAL)(Abstract No. 1288). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
36. Fessel, J., Follansbee, S. (2002, February)Effects of niacin upon fat expansion in HIV-positive patients who have the fat redistribution syndrome (FRS)(Abstract No. 703-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
37. Fichtenbaum C.J., Gerber J.G., Rosenkranz S.L., Segal Y., Aberg J.A., Blaschke T., et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 16 (2002) 569-577
38. Ganda O.P. Lipoatrophy, lipodystrophy, and insulin resistance. Annals of Internal Medicine 133 (2000) 304-306
39. Gervasoni, C., Vaccarezza M., Fedeli P. Fidolfo A. L., Rovati L. C., Galli, M. (2003, February) Long-term efficacy of buffalo hump surgical treatment in patients continuing antiretroviral therapy(Abstract No. 723). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
40. Gomez, A. F., Romero S. P., Bernal A. A., Garcia-Egido, M. A. Escobar J. J. B., Lopez-Saez, P. R. (2001, December) Dyslipidemia and hyperinsulinemia in HIV patients on HAART(Abstract No. 222). Abstract presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.
41. Gottlieb M. (2003). New treatments for facial fat wasting. Being Alive. Retrieved May 25, 2003 from http://www.beingalivela.org/news0303/newtreatmfacial_0303.html
42. Gripshover, B., Tien P. C., Saag M., Osmond D., Bacchetti P. Grundfeld, C. (2003, February) Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men(Abstract No. 732). Abstract presented at the 10th Conference of Retroviruses and Opportunistic Infections, Boston, MA.
43. Guaraldi, B. De Fazio, D., Orlando G., Murri R., Grisotti A., Nardini G., et al: (2003, February) Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome(Abstract No. 722). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
44. Hadigan C., Corcoran C., Basgoz N., Davis B., Sax P., and Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome. Journal of the American Medical Association 284 (2000) 472-477
45. Hatano H., Miller K.D., Yoder C.P., Yansvski J.A., Sebring N.G., Jones E.C., et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 14 (2000) 1935-1942
46. Heath K.V., Hogg R.S., Chan K.J., Harris M., Montessori V., O'Shaughnessy M.V., et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15 (2001) 231-239
47. Hengge, U. R., Stocks, K., Unger, S., Faulkner, S., Goos, M., & Dudley, R. (2002, February). Randomized phase III trial of oxymetholone for the treatment of HIV wasting and lipodystrophy (Abstract No. 705-T). Abstract presented at the9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
48. Hillebrand, M. E., Strackee, S. D., van Ulden, B. J., & ten Veen, J. H. (2002, July). Treatment of facial lipoatrophy with polylactic acid: The PLA-study (Abstract No. C10946). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
49. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 361 (2003) 726-735
50. Hoffman-Terry, M. L., O'Donnell, E., Wasylik, A., Wasser, T., & Saqib, M. N. (2001, December). Factors associated with hyperglycemia complicating HAART in the HIV/HCV coinfected population (Abstract No. H-740). Abstract pre-sented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.
51. Holmberg S.D., Moorman A.C., Williamson J.M., Tong T.C., Ward D.J., Wood K.C., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
52. Iloeje, U., Yuan Y., Tuomari A., L'Italien, G., Mauskopf J., Moore, R. (2003, February) Protease inhibitors may increase risk of cardiovascular disease in HIV-infected patients(Abstract No. 746). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
53. Jones S.P., Doran D.A., Seatt P.B., Maher B., and Pirmohamed M. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 15 (2001) 2049-20511
54. Kahn, J. O., Simmons K., Jacobson M., Hecht F., Deeks S., Grant R., et al: (2001, December) Trends in clinically significant disorders at San Francisco General Hospital using HIVWatch: A web based electronic clinical database(Abstract No. I-223). Abstract presented at the 41st Interscience Conference on Antimicrobrial Agents and Chemotherapy, Chicago, IL.
55. Kakuda T.N., Brundage R.C., Anderson P.L., and Fletcher C.V. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 13 (1999) 2311
56. Keiser, P., Sension M., DeJesus E., Rodriguez A., Olliffe J., Williams V. et al: (2002, July) Simplification of protease inhibitor (PI)-based highly active antiretroviral regimens with abacavir (ABC) improves hyperlipidemia and maintains viral suppression in HIV-1 infected adults(Abstract No. WePeC6267). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
57. Kemppainen, J., Kirksey K. M., Nicholas P. K., Corless I. B., Mueller, M. E. (2003, November 3) Relationship between lipodystrophy-associated morphologic/metabolic changes and depression in persons infected with HIV/AIDS(Abstract). Abstract presented at the 37th Biennial Convention- Scientific Session Sigma Theta Tau International, Toronto, Ontario Canada.
58. Kingsley, L., Smith E., Riddler S., Li R., Chmiel J., Palella F. et al: (2001, February) Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS)(Abstract No. 538). Abstract presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
59. Koko-Ekong, S., Azubike U., Ekong E., Uwah A. Akinlade, O. (2002, February) Fat redistribution in HIV patients on nonprotease inhibitor (PI) regimens-Study in 6 centres in Nigeria(Abstract No. 684-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
60. Kotler, D., Engelson E., Heymsfield S., Chang P., Muurahainen N., Gertner, J. (2002, February) Anthropometric criteria define visceral fat excess in patients with HIV-associated adipose redistribution syndrome (HARS), a subset of HIV lipodystrophy(Abstract No. 688-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
61. Kotler, D. P., Thompson, M., Grunfeld, C., Gertner J., Muurahainen, N. (2002, November) Transient insulin resistance during recombinant human growth hormone (rhGH) therapy for HIV-associated adipose redistribution syndrome (HARS)(Abstract No. LB-20). Abstract presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA.
62. Lafon, E., Bani Sadr, F., Chandemerle C., Melchior J. C., De Truchis, P., Gregoire V. et al: (2000, September) LIPSTOP study: Evolution of clinical lipodystrophy (LD), blood lipids, visceral (VAT) and subcutaneous (SAT) adipose tissue after switching from protease inhibitor (PI) to efavirenz (EFV) in HIV-1 infected patients(Abstract No. 1535). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
63. Lands L. Kiss lipo bye-bye?. POZ (2001) 52
64. Leite, A. G., Spichler, A. S. (2002, July) Hypertriglyceridemia and opportunistic infections in acquired immunodeficiency syndrome(Abstract No. C11042). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
65. Lemperle G., Romano J.J., and Busso M.M. Soft tissue augmentation with Artecoll: 10-year history, indications, technique, and potential side effects. Dermatological Surgery 29 (2002) 573-587
66. Lichtenstein, K., Delaney K., Ward D., Moorman A., Wood K., Holmberg, S. (2002, February) Incidence and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients(Abstract No. 684a-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
67. Lichtenstein K.A., Ward D.J., Moorman A.C., Delaney K.M., Young B., Palella F.J., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001) 1389-1398
68. Liss, M., Vaamonde C., Boyle, B. (2002, July)The effect of nutrition and exercise advice on lipid profiles of HIV+ patients with hyperlipidemia(Abstract No. WePeB5990). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
69. Louie J.K., Hsu L.C., Osmond D.H., Katz M.H., and Schwarcz S.K. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco. Journal of Infectious Diseases 186 (2002) 1023-1027
70. Lowe, M. R., Chuck S. K., Penzak, S. R. (2001, December) Efficacy & safety of Pravastatin in protease inhibitor-related hyperlipidemia (PIH)(Abstract No. 228). Abstract presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.
71. Madge S., Kinloch-de-Loes S., Mercey D., Johnson M.A., and Weller I.V.D. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS 13 (1999) 735
72. Manfredi R., Calza L., and Chiodo F. A life-long antiretroviral treatment of congenital HIV disease, associated with a mixed fat redistribution syndrome and osteopenia already occurred during pre-pubertal age. International Journal of STD & AIDS 13 (2002) 504-507
73. Martinez E., Bianchi L., Garcia-Viejo M.A., Bru C., and Gatell J.M. Sonographic assessment of regional fat in HIV-1-infected people. Lancet 356 (2000) 1412-1413
74. Martinez E., Conget I., Lozano L., Casamitjana R., and Gatell J.M. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13 (1999) 805-810
75. Martinez E., Garcia-Viejo M.A., Blanch L., and Gatell J.M. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Safety 24 (2001) 157-166
76. Martinez E., and Gatell J.M. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome. Current Opinion in Infectious Diseases 12 (1999) 13-19
77. Martinez, E., Romeu J., Garcia-Viejo, M. A., Cruz L., Blanco J. L., Negredo E. et al: (2001, February) An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy(Abstract No. 668). Abstract presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
78. Mary-Krause, M., Cotte, L., Partisani, M., Simon, A., & Costagliola, D. (2001, February). Impact of treatment with pro-tease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men (Abstract No. 657). Abstract presented at the 8th Conference on Retroviruses and Opportunistic Infec-tions, Chicago, IL.
79. Mauss, S., Stechel, J., Schmutz, G., Berger, F., & Richter, W. O. (2002, July). Lipoprotein patterns associated with antiretroviral therapy indicate a low cardiovascular risk (Abstract No. ThPeB7321). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
80. Mauss, S., Wolf, E., Corzillius, M., Schwenk, A., Jaeger, H., Knechten, H., et al. (2000, September). Prevalence and risk factors for the HIV-associated lipodystrophy syndrome (HALS0 in patients being 3 years on ART (Abstract No. 1287). 62 JANAC Vol. 15, No. 6, November/December 2004 Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
81. McComsey, G., Lonergan, T., Fisher, R., Sension, M., Hoppel, C., Williams, V., et al. (2002, February). Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV) (Abstract No. 701-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
82. Mehta, S., Moore, R., Thomas, D., Chaisson, R. E., & Sulkowski, M. (2002, February). The effect of HAART and HCV infection on the development of diabetes mellitus (Abstract No. 679-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
83. Mercie P., Viallard J.F., Thiebaut R., Faure I., Rispal P., Leng B., et al. Efavirenz-associated breast hypertrophy in HIV-infected patients. AIDS 15 (2001) 126-129
84. Moore, R. D. Keruly J. C., Lucas, G. (2003, February)Increasing incidence of cardiovascular disease in HIV-infected persons in care(Abstract No. 132). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
85. Moyle, G., Lysakova L., Brown S., Barton, S. (2002, November)Polylactate (NewFill) injections subjectively and objectively improve appearance and reduce anxiety and depression scores in HIV positive persons with facial lipoatrophy: A randomized, open label, immediate vs. delayed therapy study(Abstract No. 1934). Abstract presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
86. Moyle, G. J., Lloyd M., Reynolds B., Baldwin C., Mandalia S., Gazzard, B. G. (2000, September) A randomized open label trial of dietary advise with or without pravastatin for the management of protease inhibitors(Abstract No. 1296). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
87. Mugavero, M., Chen, R., Westfall, A., Cloud, G., Raper, J., Taylor, K., et al. (2003, February). Increased cost of lipodystrophy in HIV patients due to higher physician, laboratory, and medica-tion costs (Abstract No. 740). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
88. Mulligan K., Grunfeld C., Tai V.W., Algren H., Pang M., Chernoff D.N., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. Journal of Acquired Immune Deficiency Syndromes 23 (2000) 35-43
89. Neto, R. J., Colares, J. K. (2002, July) Metabolic abnormalities and lipodystrophy in AIDS patients treated with proteases inhibitors in a Brazilian HIV reference center(Abstract No. C10949). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
90. Noor M.A., Lo J.C., Mulligan K., Schwarz J.M., Halvorsen R.A., Schambelan M., et al. Metabolic effects of indinivir in healthyHIV-seronegative men. AIDS 15 (2001) F11-F18
91. Pacini S., Ruggiero M., Cammarota N., Protopapa C., and Gulisano M. Bio-Alcamid, a novel prosthetic polymer, does not interfere with morphological and functional characteristics of human skin fibroblast. Plastic and Reconstructive Surgery 111 (2003) 489-491
92. Palella F.J.Jr., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine 338 (1998) 853-860
93. Paton, N., Ng Y. M., Chua, Y-K., Aboulhab J., Karim, F. (2002, February) Comparison of regional body composition changes in lipodystrophy with those of tuberculosis-related wasting(Abstract No. 687-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
94. Piliero, P., Cahn, P., Pantaleo, G., Gatell, J. M., Squires, K., Percival, L., et al. (2002, February). Atazanavir: A once-daily protease inhibitor with a superior lipid profile: results of clini-cal trials beyond week 48 (Abstract No. 706-T). Abstract pre-sented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
95. Poizot-Martin, I., Marimoutou, C., Vion-Dury, F., Gregoire, R., Dinh, T., Djemli, K., et al. (2002, July). Follow-up of glucose metabolism in a cohort of HIV-infected patients with HAART (Abstract No. TuPeB4530). Abstract presented at the XIV International AIDS Conference, Barcelona, Spain.
96. Polo, R., Cobo, J., Alonso, M., Martinez, S., Gonzalez-Munoz, M., Madrigal, P., et al. (2001, December). Differences inabdominal fat redistribution in HIV-patients with or without lipodystrophy using computed tomography (Abstract No 224). Abstract pre-sented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.
97. Polo, R., Madrigal, P., Segarra, P., Sanz, J., Galindo, M., Pulido, F., et al. (2000, September). Prevalence of lipodystrophy and met-abolic complications in HIV-infected patients: a cross-sec-tional study (Abstract No. 1281). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemo-therapy, Toronto, Canada.
98. Polo R., Verdejo J., Martinez-Rodriguez S., Madrigal P., and Gonzalez-Munoz M. Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients. Journal of Acquired Immune Deficiency Syndrome 25 (2000) 284-286
99. Polo, R., Verdejo, J., Martinez-Rodriguez, S., Madrigal, P., & Gonzalez-Munoz, M. (2000b, September). Lipodystrophy in protease inhibitor-nave HIV-infected patients (Abstract No. 1282). Abstract presented at the 40th Interscience Conference onAntimicrobial AgentsandChemotherapy, Toronto, Canada.
100. Riesenberg, K., Rudich, A., Vanounou, S., Tirosh, A., Harman-Boehm, I., Bashan, N., et al. (2001, December). Cellular mech-anisms for insulin resistance induced by nelfinavir in adipocytes (Abstract No. 227). Abstract presented at the 41st Interscience Conference on Antimicrobial Agents and Chemo-therapy, Chicago, IL.
101. Rodriguez-Guardado, A., Maradona, J. A., Asensi, V., Carton, J. A., & Arribas, J. M. (2001, December). Triglyceride increaseNorris, Dreher / The Effects of Lipodystrophy Syndrome 63 can predict lipodystrophy in HIV patients under HAART (Abstract No. I-221). Abstract presented at the 41st Interscience Conference on Antimicrobial Agents and Chemo-therapy, Chicago, IL.
102. Roubenoff R., Weiss L., McDermott A., Heflin T., Cloutier G.J., Wood M., et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13 (1999) 1373-1375
103. Saint-Marc T., Partisani M., Poizot-Martin I., Bruno F., Rouviere O., Lang J.M., et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13 (1999) 1659-1667
104. Saint-Marc T., Partisani M., Poizot-Martin I., Rouviere O., Bruno F., Avellaneda R., et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 14 (2000) 37-49
105. Saint-Marc T., and Touraine J.L. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 13 (1999) 2188
106. Sattler F.R., Qian D., Louie S., Johnson D., Briggs W., DeQuattro V., et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 15 (2001) 2001-2010
107. Saves, M., Chene, G., Dellamonica, P., Lassalle, R., Leport, C., Capeau, J., et al. (2002, February). Incidence of lipodystrophy and glucose and lipid abnormalities during the follow-up of a cohort of HIV-infected patients started on a protease inhibitor (PI)-containing regimen (Abstract No. 682-T). Abstract pre-sented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
108. Scarsella, A. J., Dieterich, D. T., Graham, N. M. H., Fusco, G. P., Sherrill, B. H., Fusco, J. S., et al. (2000, September). Predictors of lipodystrophy in HIV-infected patients from the CHORUS observational cohort (Abstract No. 1286). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
109. Schmidt H. Where does insulin resistance in lipodystrophic HIV-1-positive subjects come from?. AIDS 15 (2001) 2187-2188
110. Stryker, R. Luber A. D., Wolfe P.R., Shaker-Irwin L., Cohan, G. (2000, September) Lipoatrophy and lipo-accumulation disorders among HIV-infected individuals in a large urban HIVpractice(Abstract No. 1285). Abstract presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
111. Tien, P. C., Cole S. R., Williams C. M., Li R., Justman J., Cohen, M. H., et al. (2003, February) Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study (Abstract No. 736). Abstract presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
112. Valencia M.E., Barreiro P., Soriano V., Blanco F., Moreno V., and Lahoz J.G. Necrosis in HIV-infected patients receiving antiretroviral treatment: Study of seven cases. HIV Clinical Trials 4 (2003) 132-136
113. Vergel N. (2002): Facial wasting: HIV-related facial wastingpotential reconstruction procedures. FacialWasting.org. Retrieved October 14, 2002, from http://www.facialwasting.org/pages/869165/index.htm
114. Vergel, N. (2003, February). HIV-related facial wasting-potential reconstructive procedures. Retrieved May 25, 2003, from http://www.facialwasting.org/pages/869165/index.htm
115. Visionary Health Concepts. LipoWatch News 1 7 (2002). http://www.vhconcepts.com/newsletter/lipo7_email.htm Retrieved May 25, 2003, from http://www.vhconcepts.com/newsletter/lipo7_email.htm
116. von Ornsteiner J.B. The lipodystrophy look 15 5 (2002). http://www.thebody.com/bp/sept02/lipodystrophy.html Retrieved November 19, 2003, From The Body Positive, Retrieved from http://www.thebody.com/bp/sept02/lipodystrophy.html
117. Ward, D. J., Delaney K. M., Lichtenstein K. A., Moorman A. C., Holmberg, S. D. (2000, September) Lipid elevations in a survey of lipodystrophy in HIV-infected ambulatory patients(Abstract No. 1294). Abstract presented at the 40th Interscience Conference on Antimicrobrial Agents and Chemotherapy, Toronto, Canada.
118. Weisberg L. (2000). Lipodystrophy remains a troublesome mystery. IAPAC Monthly, pp. 357-359
119. Woerle P.R., Mariuz C.M., Reichman R.C., Popa E.M., Dostou J.M., Welle S.L., et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52 (2003) 918-925
120. Yoon, C., Gulick R., Hoover D., Vaamonde C., Glesby, M. (2002, February) Case-control study of diabetes mellitus in HIV-infected patients(Abstract No. 678-T). Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.